Diabetes Care Gets Boost With a Cutting-Edge Insulin Plant

Chennai has now become home to the state's first—and the nation's fifth—biosimilar insulin manufacturing facility, as Regenix Drugs Ltd commissions its cutting-edge plant to produce Sustaglar, a long-acting glargine insulin.

- HD Bureau

The move is aimed at making diabetes care both more affordable and more widely available, especially in rural regions.

This milestone positions Tamil Nadu firmly within India's elite circle of biosimilar insulin producers.

Regenix's new manufacturing unit, based in Chennai, is WHO-GMP certified and designed to handle fill-finish operations for injectable biologics, including vials, pre-filled syringes and cartridges, across a product range that spans human insulin variants, insulin glargine, liraglutide and enoxaparin.